Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $11.6 million.

  • Evoke Pharma's Cash & Equivalents rose 230.15% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 230.15%. This contributed to the annual value of $13.6 million for FY2024, which is 18688.28% up from last year.
  • As of Q3 2025, Evoke Pharma's Cash & Equivalents stood at $11.6 million, which was up 230.15% from $12.1 million recorded in Q2 2025.
  • Evoke Pharma's 5-year Cash & Equivalents high stood at $18.2 million for Q1 2021, and its period low was $4.7 million during Q4 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $11.1 million (2021), whereas its average is $10.8 million.
  • Per our database at Business Quant, Evoke Pharma's Cash & Equivalents soared by 33999.87% in 2021 and then crashed by 5765.31% in 2022.
  • Over the past 5 years, Evoke Pharma's Cash & Equivalents (Quarter) stood at $9.1 million in 2021, then grew by 7.64% to $9.8 million in 2022, then tumbled by 51.85% to $4.7 million in 2023, then surged by 186.88% to $13.6 million in 2024, then dropped by 14.68% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $12.1 million for Q2 2025, and $12.6 million during Q1 2025.